AstraZeneca Pharma India Limited Revenue Breakdown – NSE:ASTRAZEN
NiveshIQ
NSE: ASTRAZEN · Pharma
AstraZenca Pharma India Ltd.
₹8,094.50▼ ₹90.50 (-1.11%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ASTRAZEN. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About AstraZenca Pharma India Ltd.
AstraZeneca Pharma India Limited is a biopharmaceutical company that manufactures, markets, and trades in pharmaceutical products in India and internationally. The company provides medicines for various conditions including cardiovascular, renal, metabolic, and immunological conditions, as well as oncology, rare diseases, and respiratory medicines. Its key revenue drivers include TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names, which have contributed to the company's 33% revenue growth. AstraZeneca Pharma India Limited has a strategic collaboration with Leica Biosystems and Daiichi Sankyo Company, Limited for the development of an immunohistochemistry assay and an image analysis algorithm for the TROP2 NMR biomarker in non-small cell lung cancer. The company has a strong pres
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,295 Cr +29.10% | ₹1,716 Cr +32.50% | ₹2,276 Cr +32.60% |
| EBITDA Margin | 14.21% | 14.80% | 12.77% |
| Net Profit | ₹161.00 Cr +62.60% | ₹115.00 Cr -28.60% | ₹192.77 Cr +67.60% |
| EPS | ₹64.60 | ₹46.29 | ₹75.01 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Enterprise value to EBIT forward of AstraZeneca Pharma India Limited – NSE:ASTRAZEN
🔒
Sign in to see AI summaries
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹683 Cr, PAT ₹38 Cr, EPS ₹15.17, EBITDA margin 8.5%. Growth context: revenue QoQ +18.0%, PAT QoQ -17.5%.
Management commentary points to product launches, approvals, and therapy-mix improvement as the primary near-term growth...
FY26 (last completed FY): revenue ₹2, 276 Cr, PAT ₹193 Cr, EBITDA margin 12.8%, EPS ₹75.01. Year-on-year: revenue YoY +3...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ASTRAZEN
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ASTRAZEN alongside your other holdings
Unlock full ASTRAZEN research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for AstraZenca Pharma India Ltd.?
NiveshIQ detects active intelligence signals for AstraZenca Pharma India Ltd. (ASTRAZEN) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for AstraZenca Pharma India Ltd.?
AstraZenca Pharma India Ltd. operates in the Pharma sector with a market capitalisation of ₹2,023,625.0L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.